Merck & Company(DE:6MK)
€131.42+0.52 (+0.40%)
DE:6MK
Merck & Company stock forecast
€131.42
At close:+0.52 (+0.40%)
Merck & Company (6MK) Stock Forecast & Price Target
70 Followers
6MK Analyst Ratings
Moderate Buy
15Buy7Hold0Sell
Based on 22 analysts giving stock ratings to Merck & Company in the past 3 months
6MK Stock 12 Month Forecast
Average Price Target
€146.11▲(11.18% Upside)Based on 22 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is EUR 146.11 with a high forecast of EUR 162.21 and a low forecast of EUR 94.62. The average price target represents a 11.18% change from the last price of EUR 131.42.
Past 12 Months12 Month ForecastJan2026Oct2026
High€162.21
Average€146.11
Low€94.62
Highest Price TargetHighest€162.21Average Price Target€146.11Lowest Price TargetLowest€94.62
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Carter Gould | Cantor Fitzgerald | €139.68 | hold | 6.29%Upside | Reiterated | 11/11/26 | ||
| Louise Chen | Scotiabank | €162.21 | buy | 23.43%Upside | Reiterated | 11/10/26 | ||
| Trung Huynh | RBC Capital | €126.17 | hold | -4.00%Downside | Reiterated | 11/05/26 | ||
| Elmar Kraus | DZ BANK AG | €137.88 | hold | 4.92%Upside | Downgraded | 11/03/26 | ||
| Daina Graybosch | Leerink Partners | €145.09→€145.99 | buy | 11.09%Upside | Reiterated | 11/02/26 | ||
| Ilya Zubkov | Freedom Capital Markets | €112.65→€126.17 | hold | -4.00%Downside | Reiterated | 11/02/26 | ||
| Jason Gerberry | Bank of America Securities | €146.89→€148.69 | buy | 13.14%Upside | Reiterated | 10/30/26 | ||
| Evan Seigerman | BMO Capital | €153.20 | buy | 16.57%Upside | Reiterated | 10/30/26 | ||
| Terence Flynn | Morgan Stanley | €159.51→€156.81 | buy | 19.32%Upside | Assigned | 10/30/26 | ||
| Chris Schott | J.P. Morgan | €148.69→€157.71 | buy | 20.00%Upside | Assigned | 10/30/26 | ||
| Vamil Divan | Guggenheim | €153.20→€154.10 | buy | 17.26%Upside | Reiterated | 10/29/26 | ||
| Emily Field | Barclays | €162.21 | buy | 23.43%Upside | Reiterated | 10/28/26 | ||
| Geoff Meacham | Citi | €130.67 | hold | -0.57%Downside | Reiterated | 10/27/26 | ||
| Mohit Bansal | Wells Fargo | €148.69 | buy | 13.14%Upside | Reiterated | 10/26/26 | ||
| Courtney Breen | Bernstein | €94.62 | hold | -28.00%Downside | Reiterated | 10/25/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Carter GouldCantor Fitzgerald | HoldReiterated€139.68 | 11/11/26 | 6.29%Upside | ||
| Louise ChenScotiabank | BuyReiterated€162.21 | 11/10/26 | 23.43%Upside | ||
| Trung HuynhRBC Capital | HoldReiterated€126.17 | 11/05/26 | -4.00%Downside | ||
| Elmar KrausDZ BANK AG | HoldDowngraded€137.88 | 11/03/26 | 4.92%Upside | ||
| Daina GrayboschLeerink Partners | BuyReiterated€145.09→€145.99 | 11/02/26 | 11.09%Upside | ||
| Ilya ZubkovFreedom Capital Markets | HoldReiterated€112.65→€126.17 | 11/02/26 | -4.00%Downside | ||
| Jason GerberryBank of America Securities | BuyReiterated€146.89→€148.69 | 10/30/26 | 13.14%Upside | ||
| Evan SeigermanBMO Capital | BuyReiterated€153.20 | 10/30/26 | 16.57%Upside | ||
| Terence FlynnMorgan Stanley | BuyAssigned€159.51→€156.81 | 10/30/26 | 19.32%Upside | ||
| Chris SchottJ.P. Morgan | BuyAssigned€148.69→€157.71 | 10/30/26 | 20.00%Upside | ||
| Vamil DivanGuggenheim | BuyReiterated€153.20→€154.10 | 10/29/26 | 17.26%Upside | ||
| Emily FieldBarclays | BuyReiterated€162.21 | 10/28/26 | 23.43%Upside | ||
| Geoff MeachamCiti | HoldReiterated€130.67 | 10/27/26 | -0.57%Downside | ||
| Mohit BansalWells Fargo | BuyReiterated€148.69 | 10/26/26 | 13.14%Upside | ||
| Courtney BreenBernstein | HoldReiterated€94.62 | 10/25/26 | -28.00%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Merck & Company
3 Months
Success Rate14/15 ratings generated profit
93%
Average Return
+10.14%
Copying Asad Haider's trades and holding each position for 3 Months would result in 93.33% of your transactions generating a profit, with an average return of +10.14% per trade.
1 Year
Success Rate15/15 ratings generated profit
100%
Average Return
+35.43%
Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +35.43% per trade.
2 Years
Success Rate15/15 ratings generated profit
100%
Average Return
+42.35%
Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +42.35% per trade.
6MK Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 44 | 52 | 54 | 64 | 42 |
| Hold | 16 | 16 | 17 | 23 | 23 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 60 | 68 | 71 | 87 | 65 |
In the current month, 6MK has received 42 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. 6MK average Analyst price target in the past 3 months is 146.11.
6MK Financial Forecast
High€1.77
Consensus€1.58
Low€1.53
6MK Earnings Forecast
Next quarter’s earnings estimate for 6MK is EUR 1.58 with a range of EUR 1.53 to EUR 1.77. The previous quarter’s EPS was EUR 2.24. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€15.1B
Consensus€14.7B
Low€14.3B
6MK Sales Forecast
Next quarter’s sales forecast for 6MK is EUR 14.68B with a range of EUR 14.34B to EUR 15.10B. The previous quarter’s sales results were EUR 16.33B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
6MK Stock Forecast FAQ
What is DE:6MK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is €146.11.
What is DE:6MK’s upside potential, based on the analysts’ average price target?
Merck & Company has 11.18% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Merck & Company a Buy, Sell or Hold?
Merck & Company has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 7 hold ratings and 0 sell ratings.
What is Merck & Company’s share price target?
The average share price target for Merck & Company is €146.11. This is based on 22 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €162.21, and the lowest forecast is €94.62. The average share price target represents a 11.18% increase from the current price of €131.42.
What do analysts say about Merck & Company?
Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Street analysts.
How can I buy shares of Merck & Company?
To buy shares of DE:6MK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
